Fixed Phage leads the design, development and commercialisation of applications, which use stabilised phage to solve bacterial challenges." title="" class="btn" data-container="body" data-html="true" data-id="149401" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#b3d4fc" tabindex="0" data-original-title="FixedPhage"> 285 3,126
Activities
Technologies
Entity types
Location
1, 2317 Maryhill Rd, Glasgow G20 0TH, UK
Glasgow
United Kingdom
Employees
Scale: 11-50
Estimated: 14
Engaged catalyst
1Added in Motherbase
3 years, 6 months agoTargeted phage technology, safeguarding human and animal health by harnessing sustainable, antibacterial technology
NexaBiome's patented technology enables bacteriophages to be covalently attached to a wide variety of substrates; this gives them enhanced stability for use in a variety of applications which address two of the world's major challenges, antibiotic resistance and food supply and sustainability.
By attaching specific bacteriophages to fish and animal feeds, we can reduce, augment or even substitute for antibiotics in the food chain. This lets us target both human and animal pathogens, such as E. coli, Listeria, Campylobacter, Salmonella, Streptococcus, Pseudomonas, Flavobacteria and others.
As our bonded phage products can be stable for months or even years and are less sensitive to temperature and other environmental factors, they can be effectively shipped and applied in versatile formulations
Bacteriophages also have many potential human applications when antibiotics fail. Phages are expert microbiome engineers and can specifically alter the bacterial microbiome of the human gut, skin, vagina, lung and other micro-environments. Microbiome engineering has important applications to irritable bowel syndrome, acne, bacterial vaginosis and bacterial lung diseases. Our ability to attach bacteriophages to micro- and nano-particles and to enhance their stability and active life span, can potentially enhance their effectiveness in these applications, whether as part of a probiotic supplement or as encapsulated powders/beads.
Probiotic Feeds, Antibiotic Resistance, Food Wastage, Zinc Oxide Replacement, Formaldehyde Replacement, Aquaculture, Poultry, Microbiome, Active Packaging, Veterinary Health, Tilapia, Salmonids, Shelf Life Extension, AgriScience, MRSA, E.coli, Pseudomonas, Campylobacter, and Listeria
Our mission is to deliver innovative and effective solutions to tackle antimicrobial resistance (AMR) and to be the leading end-to-end phage company.
Catalyst | Type | Tweets | Articles | |
---|---|---|---|---|
![]() The Yield Lab Venture Capital and Private Equity Principals | The Yield Lab Venture Capital and Private Equity Principals | Not capitalistic Not partnership Event 20 Sep 2018 | |